Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday, Zacks reports.
Several other equities research analysts have also recently weighed in on TEVA. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Oppenheimer increased their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 9th. TD Cowen raised their price objective on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Finally, Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.64.
Check Out Our Latest Stock Analysis on TEVA
Teva Pharmaceutical Industries Stock Down 8.8%
Teva Pharmaceutical Industries stock opened at $38.53 on Wednesday. Teva Pharmaceutical Industries has a 1-year low of $24.01 and a 1-year high of $44.57. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The stock has a market cap of $44.90 billion, a PE ratio of 89.61, a P/E/G ratio of 3.66 and a beta of 0.97. The stock’s fifty day moving average is $40.56 and its two-hundred day moving average is $35.22.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same period in the prior year, the firm posted $0.78 EPS. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, sell-side analysts expect that Teva Pharmaceutical Industries will post 1.98 EPS for the current fiscal year.
Insider Buying and Selling at Teva Pharmaceutical Industries
In related news, insider Mark Sabag sold 46,000 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $41.93, for a total value of $1,928,780.00. Following the completion of the sale, the insider directly owned 80,760 shares of the company’s stock, valued at $3,386,266.80. This represents a 36.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the transaction, the insider owned 8,500 shares in the company, valued at $330,225. This represents a 46.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 715,945 shares of company stock valued at $29,061,351. 0.54% of the stock is owned by insiders.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
A number of hedge funds have recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Teva Pharmaceutical Industries by 1.3% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock worth $1,561,120,000 after purchasing an additional 500,000 shares during the period. Goldman Sachs Group Inc. increased its stake in Teva Pharmaceutical Industries by 20.0% in the third quarter. Goldman Sachs Group Inc. now owns 7,355,669 shares of the company’s stock valued at $291,284,000 after purchasing an additional 1,226,429 shares during the period. Wellington Management Group LLP raised its holdings in shares of Teva Pharmaceutical Industries by 5.8% in the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after buying an additional 419,329 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Teva Pharmaceutical Industries by 1.5% in the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after buying an additional 72,880 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $110,197,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting Teva Pharmaceutical Industries
Investors following TEVA have been watching these stories:
- Positive Sentiment: Barclays raised its price target to $50 from $47 and maintained an Overweight rating. Argus also raised its target to $50 and reaffirmed a Buy rating, while HC Wainwright maintained its Buy rating. Barclays analyst action Argus forecast HC Wainwright rating
- Neutral Sentiment: Teva said its R&D strategy, priorities and commitments remain unchanged, including its goal of $6–7 billion in innovative-medicines revenue by 2030. David Gardiner will lead the transition while the company searches for a permanent successor. Teva leadership announcement
- Negative Sentiment: Executive Vice President of Global R&D and Chief Medical Officer Eric Hughes is leaving for an opportunity outside Teva. His departure may unsettle investors given the importance of R&D execution to the company’s growth strategy, despite his planned support during the transition. R&D leadership transition report
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Further Reading
- Five stocks we like better than Teva Pharmaceutical Industries
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
